Isabella Ciccone, Assistant Editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter @iciccone7 or email her at iciccone@mjhlifesciences.com
Satralizumab Continues to Show Long-Term Efficacy in AQP4-IgG-Seropositive NMOSD
October 12th 2023A new analysis of the SAkuraMoon study showed that annual relapse rate remained consistently low in satralizumab-treated patients, with high proportions of patients remaining free from relapse, severe relapse, and worsening in disability.
Compliment C5 Inhibitors in NMOSD Safe Following Rituximab Use
October 11th 2023A recent analysis of the PREVENT and CHAMPION-NMOSD found no significant differences in safety outcomes for patients with AQP4+ NMOSD who were treated with rituximab prior to starting C5 complement inhibitors in specific timeframes.
Potassium Channel Opener XEN1101 Offers Simplicity and Strong Efficacy in Seizure Control
October 10th 2023Jacqueline French, MD, professor of neurology at NYU Grossman School of Medicine and chief medical officer of the Epilepsy Foundation, talked about findings from a newly published study assessing XEN1101 in patients with drug-resistant epilepsy.
PIRA Identified as the Most Common Form of Disability Accumulation in Multiple Sclerosis
October 4th 2023Researchers proposed a harmonized definition of progression independent of relapse activity that may improve the comparability of results in current and future study cohorts, according to a newly published systematic review.
Novel Insights on Orexin Receptor TAK-994 and its Discontinued Narcolepsy Study
October 4th 2023Elena Koundourakis, PhD, head of orexin franchise development at Takeda, talked about the phase 2 trial investigating TAK-994 in patients with narcolepsy type 1, which showed significant improvements in wakefulness, despite discontinuation because of hepatotoxicity.
Significant Care Access Disparities Found Among Older Patients With Cognitive Decline Living Alone
October 3rd 2023A recent finding from a qualitative study raises concerns about patient safety in healthcare because the system in the US is not well equipped to address the unique needs of older adults living alone with cognitive decline.
Neuro News Roundup: LGMD Awareness Day – Expert Insight and Latest Literature
September 30th 2023In honor of Limb-Girdle Muscular Dystrophy Awareness Day, held September 30, 2023, get caught up on some of the latest news in LGMD, with data updates and expert insights all in one place from the NeurologyLive® team.
Clinical Insights on the Emerging Trends in Research for NMOSD and MOGAD
September 29th 2023Erin Longbrake, MD, PhD, associate professor of neurology at Yale School of Medicine, discussed the importance of understanding rare autoimmune disorders to effectively design clinical trials and treatment strategies, especially for heterogeneous conditions like NMOSD and MOGAD.
NeurologyLive® Clinician of the Month Spotlight: Peter B. Kang, MD, FAAN, FAAP
September 28th 2023As part of our monthly clinician spotlight, NeurologyLive® highlighted neueomuscular expert Peter Kang, MD, director of the Paul and Sheila Wellstone Muscular Dystrophy Center and professor of neurology at the University of Minnesota.
Disparities in Memory Clinic Visits and Dementia Severity Identified in Disadvantaged Neighborhoods
September 28th 2023Patients who self-identified as Black and were living in less affluent neighborhoods were less likely to be seen in one large memory clinic as well as have more severe dementia at initial visit.
Standard and Nonstandard Physical Therapy Show Similar Effectiveness for Parkinson Disease
September 26th 2023Although research supports the use of physical therapy as an effective treatment for Parkinson disease, implementation factors including type, timing, frequency, and durability of outcomes remain mainly untouched.
New Interim Data Reported on DNL310 for Hunter Syndrome Treatment in Phase 1/2 Trial
September 26th 2023Additional biomarker findings from up to 2 years of DNL310 treatment suggest positive changes in adaptive behavior and cognition as well as improvement in auditory function among pediatric patients with Hunter syndrome.
CNM-Au8 Shows Significant Long-Term Survival Improvement in HEALEY ALS Platform Trial
September 25th 2023In an integrated meta-analysis of the HEALEY ALS platform trial and RESCUE-ALS trial, 30mg of CNM-Au8 resulted in 59% decreased risk of mortality among participants with ALS compared with PRO-ACT matched placebo over long-term follow-up.
BXCL501 Meets Primary Efficacy End Point in Phase 3 TRANQUILITY II Trial of Alzheimer Agitation
September 23rd 2023Among 443 episodes in 149 patients treated with different doses of BXCL501 over 12 weeks, the 60 mcg dose showed a reduction in agitation for the first and all treated episodes at 1 and 2 hours.
Targeting Cognitive Impairment of Long COVID With Brain Stimulation
September 21st 2023Leigh Charvet, PhD, professor of neurology at the NYU Grossman School of Medicine, talked about a trial that aims to address cognitive impairment in patients with long COVID through a unique, remote, and home-based treatment approach.
Limited Eligibility Among Older Adults for New Alzheimer Monoclonal Antibody Therapies
September 21st 2023A study examining eligibility criteria for Alzheimer agent trials showed that a significant proportion of older adults with early cognitive impairment may not qualify for these therapies because of health conditions and other factors.
Narcolepsy Potentially Identified as a Symptom of Immediate Food Allergic Reactions in Pediatrics
September 20th 2023In a large cohort of 848 pediatric participants with challenge-proven food allergy, investigators identified narcolepsy-like sleepiness as a symptom impacting more than 1 in 10 patients with food allergies.